Contact Information

61 Biopolis Drive
Singapore 138673
Fax: +65 6779 1117

Click here for information on how to find IMCB

Event Videos Archive

Click here to Event Videos Archive

  UPCOMING EVENTS   Selected Seminar        
Date: 17 July 2017
Time: 9:00am | (No registration required)| Level 3, IMCB Seminar Room 3-46, Proteos
Speaker: Prof. Hartmut Juhl
Title: Tissue quality and clinical data: bottleneck for biomarker and drug development

Indivumed is addressing a major challenge in individualizing cancer therapy: availability of a global clinical data base aligned with tissue that fully reflects the molecular and biological complexity of cancer. Precision medicine will only improve cancer care when we understand the biological complexity of each individual tumor. Thereby, understanding the tumor phenotype is essential for further progress. However, it is demonstrated that gene- and proteinexpression depend on tissue processing intra- and post- surgery. Within minutes of cold ischemia time, phosphorylation of signaling molecules but also cancer relevant receptors (e.g. EGFR and, possibly, PD-L1) are changing their expression levels making it almost impossible to understand tumor complexity and immuno-phenotypes accurately when tissues are not collected in an uniform and rapid way (i.e., within 10 minutes after completion of surgical resection). The lack of standardized tissue collection processes in preclinical and clinical research probably contribute to the fact that almost 90% of academic landmark studies cannot be reproduced and 90 % of new compounds fail in the clinical development phase. Implementing high tissue quality standards in cancer research can make the difference between failure and success of new drug or diagnostic development. Thereby development costs can be reduced and, last-but-not-least, more drugs with better tests will become available to improve cancer care.

Discussion: 11:00AM – 12:00PM (Registration required, please RSVP to

Introduction of the “Indivumed/Global cancer database” and the “Biobank collaboration plans".

Dr. Hartmut Juhl is an entrepreneur, surgical oncologist, and world-renowned researcher dedicated to the science of tissue quality and its application to precision medicine in cancer diagnostics and therapeutics. Hartmut holds a professorship at the Medical Faculty of Hamburg University, is an adjunct professor at the Lombardi Cancer Center of Georgetown University, and has served as an advisor to the U.S. National Cancer Institute on matters of tissue quality for clinical and research applications. From 1987 to 1992, he worked as a research associate and resident at the Hamburg-Eppendorf Surgical University Clinic. In 1992 he moved to the Surgical Clinic of the Christians Albrecht University in Kiel, where he worked as a surgical oncologist and, simultaneously, led a molecular oncology research group until 1998. He became a specialist in general surgery (“Facharzt”) in 1995. In 1999, he became Associate
Professor at the Lombardi Cancer Center of Georgetown University. In 2002, Hartmut became co-founder of Indivumed GmbH in Hamburg and was awarded the “Hamburg Foundation Prize” in the category of “Founders of new Businesses” in 2003, as well as the German Foundation Prize in the category of

“New Visionary” in 2005. In 2004, he founded Indivumed Inc, a subsidiary of Indivumed GmbH, to cover the US business. In 2008, Hartmut initiated the foundation of Inostics GmbH, a subsidiary of Indivumed GmbH, jointly owned with scientists from Johns Hopkins University, Baltimore, Maryland. In 2011 Hartmut founded IndivuTest, a specialized diagnostic lab to individualize cancer therapy, as a subsidiary of Indivumed. He successfully closed six rounds of financing to build up and grow Indivumed GmbH and its subsidiaries, respectively, and in 2013, he successfully managed the sale of Inostics GmbH to Sysmex Corporation. Hartmut studied medicine at the Hamburg-Eppendorf University Clinic from 1979 to 1986. He received his doctorate of medicine (Dr. med.) in 1989, and his “Habilitation” in Surgical Oncology in 1996.

Host: Dr. Manikandan Lakshmanan


(C) Copyright 2012 Institute of Molecular and Cell Biology, A*STAR Singapore.